Abstract
Scientific drug design enables the production of novel agents that may be specific for individual malaria species, particularly by targeting their methods of cellular entry. Though there are practical and theoretical barriers to introducing novel agents into clinical practice, there may also be theoretical benefits to encourage further investigation of such agents, including a reduction in the rate of development of falciparum resistance. This paper discusses the potential risks and benefits such agents using the example of CCR5 blockers, drugs which are already in use for HIV treatment, but may be able to block DARC, the site of Plasmodium vivax into the human red blood cell.
Keywords: DARC, malaria, chemokine receptors, Scientific drug design, novel agents, individual malaria species, theoretical barriers, falciparum resistance, Plasmodium vivax, Plasmodium, human red blood cell, falciparum, thalassemia, antimicrobials, pathogen
Infectious Disorders - Drug Targets
Title:Shooting At the DARC: Potential Issues with Species-Specific Antimalarials
Volume: 12 Issue: 5
Author(s): I. Woolley and K. Horne
Affiliation:
Keywords: DARC, malaria, chemokine receptors, Scientific drug design, novel agents, individual malaria species, theoretical barriers, falciparum resistance, Plasmodium vivax, Plasmodium, human red blood cell, falciparum, thalassemia, antimicrobials, pathogen
Abstract: Scientific drug design enables the production of novel agents that may be specific for individual malaria species, particularly by targeting their methods of cellular entry. Though there are practical and theoretical barriers to introducing novel agents into clinical practice, there may also be theoretical benefits to encourage further investigation of such agents, including a reduction in the rate of development of falciparum resistance. This paper discusses the potential risks and benefits such agents using the example of CCR5 blockers, drugs which are already in use for HIV treatment, but may be able to block DARC, the site of Plasmodium vivax into the human red blood cell.
Export Options
About this article
Cite this article as:
Woolley I. and Horne K., Shooting At the DARC: Potential Issues with Species-Specific Antimalarials, Infectious Disorders - Drug Targets 2012; 12 (5) . https://dx.doi.org/10.2174/187152612804142189
DOI https://dx.doi.org/10.2174/187152612804142189 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Advances of Inorganic Materials in the Detection and Therapeutic Uses against Coronaviruses
Current Medicinal Chemistry Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Synthesis and Applications of Glyconanoparticles
Current Organic Chemistry Synthesis of Novel 1,4-Substituted 1,2,3-Triazoles by Water-Soluble (Salicyladimine) <sub>2</sub>Cu Complex Catalyzed Azide-Alkyne Cycloaddition in Water
Letters in Organic Chemistry Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy
Clinical Cancer Drugs Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Anti-Cancer Activities of Tea Epigallocatechin-3-Gallate in Breast Cancer Patients under Radiotherapy
Current Molecular Medicine Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology